Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study

Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated... IntroductionChimeric antigen receptor T-cell (CAR T) therapy offers a potentially curative option for patients with relapsed and refractory hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL). Patient-reported experiences with CAR T therapy are limited and have not been well characterized. The purpose of this qualitative study was to explore patient descriptions of key domains of health-related quality of life (HRQoL) in DLBCL patients treated with CAR T therapy.MethodsA targeted literature review was initially conducted to inform the development of the interview guide comprising predetermined open-ended questions. Two focus groups were conducted with a total of 18 patients with DLBCL identified from patient advisory boards. Focus group sessions were recorded and transcribed verbatim. MAXQDA 18.2.0 qualitative data analysis software was utilized to facilitate a constant-comparative coding process to identify key concepts.ResultsEight domain impairments (social functioning, emotional functioning, fatigue, physical functioning, cognitive functioning, role functioning, sleep, and pain/discomfort) were identified from the qualitative analysis and endorsed by DLBCL patients treated with CAR T. Compared with before CAR T therapy, patients reported increased impairment in every domain during or immediately after CAR T therapy. This impairment improved for each domain 6 months after CAR T therapy except for pain/discomfort. Compared with before CAR T therapy, improvement in impairment for each domain was observed 6 months after CAR T therapy except for fatigue, sleep, and pain/discomfort.ConclusionThis study provides meaningful information regarding the impact of CAR T therapy on HRQoL in patients with DLBCL throughout their treatment journey. Health care professionals and investigators can utilize these data in examining existing patient-reported outcome (PRO) measures that are used in DLBCL clinical trials and to better understand the needs of DLBCL survivors. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study

Download PDF
19 pages

Loading next page...
 
/lp/springer-journals/patient-perspectives-on-health-related-quality-of-life-in-diffuse-j219mSLI03
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2021
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-021-00174-0
Publisher site
See Article on Publisher Site

Abstract

IntroductionChimeric antigen receptor T-cell (CAR T) therapy offers a potentially curative option for patients with relapsed and refractory hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL). Patient-reported experiences with CAR T therapy are limited and have not been well characterized. The purpose of this qualitative study was to explore patient descriptions of key domains of health-related quality of life (HRQoL) in DLBCL patients treated with CAR T therapy.MethodsA targeted literature review was initially conducted to inform the development of the interview guide comprising predetermined open-ended questions. Two focus groups were conducted with a total of 18 patients with DLBCL identified from patient advisory boards. Focus group sessions were recorded and transcribed verbatim. MAXQDA 18.2.0 qualitative data analysis software was utilized to facilitate a constant-comparative coding process to identify key concepts.ResultsEight domain impairments (social functioning, emotional functioning, fatigue, physical functioning, cognitive functioning, role functioning, sleep, and pain/discomfort) were identified from the qualitative analysis and endorsed by DLBCL patients treated with CAR T. Compared with before CAR T therapy, patients reported increased impairment in every domain during or immediately after CAR T therapy. This impairment improved for each domain 6 months after CAR T therapy except for pain/discomfort. Compared with before CAR T therapy, improvement in impairment for each domain was observed 6 months after CAR T therapy except for fatigue, sleep, and pain/discomfort.ConclusionThis study provides meaningful information regarding the impact of CAR T therapy on HRQoL in patients with DLBCL throughout their treatment journey. Health care professionals and investigators can utilize these data in examining existing patient-reported outcome (PRO) measures that are used in DLBCL clinical trials and to better understand the needs of DLBCL survivors.

Journal

Oncology and Therapy – Springer Journals

Published: Jun 1, 2022

Keywords: Chimeric antigen receptor (CAR) T-cell therapy; Diffuse large B-cell lymphoma; DLBCL; Health-related quality of life; HRQoL; Non-Hodgkin lymphoma; Patient-reported outcome

References

  • Diffuse large B-cell lymphoma
    Hunt, KE; Reichard, KK
  • 2016 US lymphoid malignancy statistics by World Health Organization subtypes
    Teras, LR; DeSantis, CE; Cerhan, JR; Morton, LM; Jemal, A; Flowers, CR
  • Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    Tilly, H; da Silva, MG; Vitolo, U
  • Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
    Liu, Y; Barta, SK
  • Extranodal diffuse large B cell lymphoma: molecular features, prognosis, and risk of central nervous system recurrence
    Ollila, TA; Olszewski, AJ
  • NCCN guidelines insights: B-cell lymphomas, version 3.2019
    Zelenetz, AD; Gordon, LI; Abramson, JS
  • Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma
    Chiappella, A; Santambrogio, E; Castellino, A; Nicolosi, M; Vitolo, U
  • Relapsed/refractory diffuse large B-cell lymphoma
    Friedberg, JW
  • Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
    Crump, M; Neelapu, SS; Farooq, U
  • Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era
    Nagle, SJ; Woo, K; Schuster, SJ
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
    Philip, T; Guglielmi, C; Hagenbeek, A
  • Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors
    Telio, D; Fernandes, K; Ma, C
  • Chimeric antigen receptor T-cell therapies for lymphoma
    Brudno, JN; Kochenderfer, JN
  • Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
    Neelapu, SS; Locke, FL; Bartlett, NL
  • Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
    Schuster, SJ; Bishop, MR; Tam, CS
  • Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
    Abramson, JS; Palomba, ML; Gordon, LI
  • Patient-reported outcomes in integrative oncology: bridging clinical care with research
    Lopez, G; Lacey, J; Christie, AJ
  • Harnessing the power of patient-reported outcomes in oncology
    Nipp, RD; Temel, JS
  • Patient reported outcomes have arrived: a practical overview for clinicians in using patient reported outcomes in oncology
    Warsame, R; D'Souza, A
  • Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers
    Zagadailov, E; Fine, M; Shields, A
  • The burden of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): a systematic literature review (SLR) [poster]
    Lenz, G; Rutherford, SC; Davies, A
  • ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
    Lee, DW; Santomasso, BD; Locke, FL
  • Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
    Neelapu, SS; Tummala, S; Kebriaei, P
  • Patient-reported outcomes labeling for products approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010–2014)
    Gnanasakthy, A; DeMuro, C; Clark, M; Haydysch, E; Ma, E; Bonthapally, V
  • Use of PRO measures to inform tolerability in oncology trials: implications for clinical review, IND safety reporting, and clinical site inspections
    Kim, J; Singh, H; Ayalew, K
  • The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology
    Aaronson, NK; Ahmedzai, S; Bergman, B
  • The functional assessment of cancer therapy scale: development and validation of the general measure
    Cella, DF; Tulsky, DS; Gray, G
  • A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy—Lymphoma Symptom Index
    Hlubocky, FJ; Webster, K; Beaumont, J
  • The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue
    Smets, EM; Garssen, B; Bonke, B; De Haes, JC
  • EQ-5D: a measure of health status from the EuroQol Group
    Rabin, R; de Charro, F
  • The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008
    Cella, D; Riley, W; Stone, A
  • The validity and reproducibility of a work productivity and activity impairment instrument
    Reilly, MC; Zbrozek, AS; Dukes, EM
  • Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis
    Grigor, EJM; Fergusson, D; Kekre, N
  • PRO development: rigorous qualitative research as the crucial foundation
    Lasch, KE; Marquis, P; Vigneux, M
  • Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities
    Chakraborty, R; Sidana, S; Shah, GL; Scordo, M; Hamilton, BK; Majhail, NS
  • Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily
    Tholstrup, D; Brown, PDN; Jurlander, J; Jeppesen, PB; Groenvold, M
  • Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma
    Thompson, CA; Yost, KJ; Maurer, MJ
  • Quality of life more impaired in younger than in older diffuse large B cell lymphoma survivors compared to a normative population: a study from the population-based PROFILES registry
    van der Poel, MW; Oerlemans, S; Schouten, HC
  • Patient experience of chimeric antigen receptor (CAR)-T cell therapy vs. stem cell transplant: longitudinal patient reported adverse events, cognition and quality of life
    Sidana, S; Thanarajasingam, G; Griffin, J
  • Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy
    Ruark, J; Mullane, E; Cleary, N
  • Living with a rare disorder: a systematic review of the qualitative literature
    von der Lippe, C; Diesen, PS; Feragen, KB
  • Patient-reported disease burden in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma: results from a national patient advocacy survey
    Price, M; Ravelo, A; Sae-Hau, M
  • CAR T cell toxicity: current management and future directions
    Yáñez, L; Sánchez-Escamilla, M; Perales, MA
  • Quality of life of caregivers of hematopoietic cell transplant recipients
    Jamani, K; Onstad, LE; Bar, M
  • Patient-reported outcomes in health economic decision-making: a changing landscape in oncology
    Pratt-Chapman, M; Bhadelia, A
  • International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia
    Van de Poll-Franse, L
  • Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments
    Schwenkglenks, M; Matter-Walstra, K
  • PROMIS® adult health profiles: efficient short-form measures of seven health domains
    Cella, D
  • PROMIS®-29 v2.0 profile physical and mental health summary scores
    Hays, RD
  • Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy
    Smets, EM